Insmed announces positive results from Phase III arise study of ARIKAYCE
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Health Assurance is a unique healthcare model that combines health insurance with preventive healthcare with a focus on keeping people healthy while providing sick care for them when needed
Robots make it to the healthcare conference panel, reflecting the future potential of technology
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden
Subscribe To Our Newsletter & Stay Updated